Verastem raises $250M as KRAS inhibitor shows promise in pancreatic cancer
Verastem Oncology announced encouraging early results for its KRAS G12D inhibitor in pancreatic cancer patients alongside a $250 million fundraise and CEO departure, positioning itself as a competitor to Revolution Medicines in next-generation KRAS treatments.
